AlloVir Inc. stockholders vote to merge with Kalaris Therapeutics, Inc.
The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions.
(Image credit: AdobeStock/Sapiens)
Kalaris Therapeutics, Inc. and AlloVir, Inc.release the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. In this session, the AlloVir stockholders voted in favor of all proposals at the Special Meeting, which includes to approve the proposed merger between the companies.1
According to the press release from Kalaris Therapeutics, the closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger, the combined company is expected to be renamed Kalaris Therapeutics, Inc. and trade on The Nasdaq Capital Market under the ticker “KLRS.”1
About Kalaris
Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. TH103 is currently being evaluated in an ongoing, Phase 1 clinical trial for the treatment of neovascular age-related macular degeneration, with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic eacular Edema, and Retinal Vein Occlusion.1
About AlloVir
AlloVir is an allogeneic T cell immunotherapy company that was focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems.1
